Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)

被引：13
|
作者：
Wolter, P.
Stefan, C.
Decallonne, B.
Dumez, H.
Fieuws, S.
Wildiers, H.
Clement, P.
Debaere, D.
Van Oosterom, A.
Schoffski, P.
机构：
[1] Katholieke Univ Leuven Hosp, Louvain, Belgium
[2] Catholic Univ Louvain, B-3000 Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5126
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)
    Choueiri, Toni K.
    Pal, Sumanta Kumar
    McDermott, David F.
    Ramies, David A.
    Morrissey, Stephanie
    Lee, Yihua
    Miles, Dale
    Holland, Jaymes
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su)
    Berger, Raanan
    Keizman, Daniel
    Ish-Shalom, Maya
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Pili, Roberto
    Boursi, Ben
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Peer, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] A phase II study of depsipeptide (Dep) in patients (pts) with metastatic renal cell cancer (RCC)
    Stadler, WM
    Swerdloff, JN
    Margolin, K
    McCulloch, B
    Thompson, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 420S - 420S
  • [34] Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer
    Powles, T.
    Chowdhury, S.
    Avril, N.
    Bomanji, J.
    Shamash, J.
    Sarwar, N.
    Rockall, A.
    Sahdev, A.
    Nathan, P. D.
    Kayani, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [35] A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).
    Hutson, T. E.
    Bukowski, R. M.
    Rini, B. I.
    Gore, M. E.
    Larkin, J. M. G.
    Figlin, R. A.
    Barrios, C. H.
    Escudier, B.
    Lin, X.
    Fly, K. D.
    Martell, B.
    Matczak, E.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Phase II study of CC-5013 in patients (pts) with renal cell cancer (RCC).
    Chapa, P
    Rawat, A
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 446S - 446S
  • [37] Hypertension and myelosuppression as biomarkers of sunitinib efficacy in Chinese patients (pts) with metastatic renal cell carcinoma (mRCC)
    Qin, Shukui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Jian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [38] WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib
    George, S.
    Richmond, A.
    Elson, P.
    Jin, T.
    Wood, L.
    Garcia, J. A.
    Rini, B. I.
    Finke, J.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) plus pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.
    Grunwald, Viktor
    Powles, Thomas
    Kopyltsov, Evgeny
    Kozlov, Vadim
    Gordoa, Teresa Alonso
    Eto, Masatoshi
    Hutson, Thomas E.
    Motzer, Robert J.
    Winquist, Eric
    Maroto-Rey, Pablo
    Keam, Bhumsuk
    Procopio, Giuseppe
    Wong, Shirley
    Melichar, Bohuslav
    Rolland, Frederic
    Oya, Mototsugu
    Rodriguez-Lopez, Karla
    Saito, Kenichi
    Smith, Alan D.
    Porta, Camillo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Heterogeneity of intermediate prognosis patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib
    Sella, Avishay
    Michaelson, M. Dror
    Matczak, Ewa M.
    Simantov, Ronit
    Lechuga, Mariajose
    Lin, Xun
    Figlin, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345